nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—CYP2A6—Tamoxifen—pancreatic cancer	0.0948	0.168	CbGbCtD
Eletriptan—CYP2A6—Fluorouracil—pancreatic cancer	0.0698	0.123	CbGbCtD
Eletriptan—CYP2C19—Tamoxifen—pancreatic cancer	0.0392	0.0693	CbGbCtD
Eletriptan—CYP2C9—Tamoxifen—pancreatic cancer	0.0326	0.0576	CbGbCtD
Eletriptan—ABCB1—Tamoxifen—pancreatic cancer	0.0316	0.0559	CbGbCtD
Eletriptan—CYP2D6—Tamoxifen—pancreatic cancer	0.0298	0.0527	CbGbCtD
Eletriptan—ABCB1—Gemcitabine—pancreatic cancer	0.0272	0.0482	CbGbCtD
Eletriptan—ABCB1—Erlotinib—pancreatic cancer	0.0269	0.0475	CbGbCtD
Eletriptan—CYP2D6—Erlotinib—pancreatic cancer	0.0253	0.0448	CbGbCtD
Eletriptan—ABCB1—Irinotecan—pancreatic cancer	0.0243	0.0429	CbGbCtD
Eletriptan—CYP2C9—Fluorouracil—pancreatic cancer	0.024	0.0425	CbGbCtD
Eletriptan—CYP3A4—Tamoxifen—pancreatic cancer	0.0189	0.0335	CbGbCtD
Eletriptan—ABCB1—Docetaxel—pancreatic cancer	0.0178	0.0315	CbGbCtD
Eletriptan—ABCB1—Sunitinib—pancreatic cancer	0.0177	0.0313	CbGbCtD
Eletriptan—CYP3A4—Erlotinib—pancreatic cancer	0.0161	0.0285	CbGbCtD
Eletriptan—CYP3A4—Irinotecan—pancreatic cancer	0.0146	0.0257	CbGbCtD
Eletriptan—ABCB1—Doxorubicin—pancreatic cancer	0.0133	0.0235	CbGbCtD
Eletriptan—CYP2D6—Doxorubicin—pancreatic cancer	0.0125	0.0221	CbGbCtD
Eletriptan—CYP3A4—Docetaxel—pancreatic cancer	0.0107	0.0188	CbGbCtD
Eletriptan—CYP3A4—Sunitinib—pancreatic cancer	0.0106	0.0188	CbGbCtD
Eletriptan—CYP3A4—Doxorubicin—pancreatic cancer	0.00795	0.0141	CbGbCtD
Eletriptan—Rash—Sunitinib—pancreatic cancer	0.000187	0.00063	CcSEcCtD
Eletriptan—Dermatitis—Sunitinib—pancreatic cancer	0.000186	0.00063	CcSEcCtD
Eletriptan—Abdominal distension—Doxorubicin—pancreatic cancer	0.000186	0.000629	CcSEcCtD
Eletriptan—Urticaria—Fluorouracil—pancreatic cancer	0.000185	0.000626	CcSEcCtD
Eletriptan—Headache—Sunitinib—pancreatic cancer	0.000185	0.000626	CcSEcCtD
Eletriptan—Syncope—Docetaxel—pancreatic cancer	0.000185	0.000625	CcSEcCtD
Eletriptan—Dysphagia—Doxorubicin—pancreatic cancer	0.000185	0.000624	CcSEcCtD
Eletriptan—Asthma—Doxorubicin—pancreatic cancer	0.000185	0.000624	CcSEcCtD
Eletriptan—Influenza—Doxorubicin—pancreatic cancer	0.000185	0.000624	CcSEcCtD
Eletriptan—Leukopenia—Docetaxel—pancreatic cancer	0.000185	0.000624	CcSEcCtD
Eletriptan—Pollakiuria—Epirubicin—pancreatic cancer	0.000185	0.000623	CcSEcCtD
Eletriptan—Body temperature increased—Fluorouracil—pancreatic cancer	0.000185	0.000623	CcSEcCtD
Eletriptan—Palpitations—Docetaxel—pancreatic cancer	0.000182	0.000616	CcSEcCtD
Eletriptan—Weight increased—Epirubicin—pancreatic cancer	0.000182	0.000614	CcSEcCtD
Eletriptan—Loss of consciousness—Docetaxel—pancreatic cancer	0.000181	0.000613	CcSEcCtD
Eletriptan—Weight decreased—Epirubicin—pancreatic cancer	0.000181	0.000611	CcSEcCtD
Eletriptan—Hyperglycaemia—Epirubicin—pancreatic cancer	0.00018	0.000609	CcSEcCtD
Eletriptan—Cough—Docetaxel—pancreatic cancer	0.00018	0.000608	CcSEcCtD
Eletriptan—Angina pectoris—Doxorubicin—pancreatic cancer	0.00018	0.000608	CcSEcCtD
Eletriptan—Hypersensitivity—Irinotecan—pancreatic cancer	0.00018	0.000606	CcSEcCtD
Eletriptan—Convulsion—Docetaxel—pancreatic cancer	0.000179	0.000604	CcSEcCtD
Eletriptan—Hypertension—Docetaxel—pancreatic cancer	0.000178	0.000602	CcSEcCtD
Eletriptan—Drowsiness—Epirubicin—pancreatic cancer	0.000178	0.000602	CcSEcCtD
Eletriptan—Bronchitis—Doxorubicin—pancreatic cancer	0.000178	0.000601	CcSEcCtD
Eletriptan—Myalgia—Docetaxel—pancreatic cancer	0.000176	0.000594	CcSEcCtD
Eletriptan—Arthralgia—Docetaxel—pancreatic cancer	0.000176	0.000594	CcSEcCtD
Eletriptan—Nausea—Sunitinib—pancreatic cancer	0.000176	0.000594	CcSEcCtD
Eletriptan—Asthenia—Irinotecan—pancreatic cancer	0.000175	0.000591	CcSEcCtD
Eletriptan—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000175	0.00059	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000175	0.000589	CcSEcCtD
Eletriptan—Stomatitis—Epirubicin—pancreatic cancer	0.000174	0.000587	CcSEcCtD
Eletriptan—Conjunctivitis—Epirubicin—pancreatic cancer	0.000173	0.000585	CcSEcCtD
Eletriptan—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000172	0.000581	CcSEcCtD
Eletriptan—Dry mouth—Docetaxel—pancreatic cancer	0.000172	0.000581	CcSEcCtD
Eletriptan—Sweating—Epirubicin—pancreatic cancer	0.000171	0.000577	CcSEcCtD
Eletriptan—Pollakiuria—Doxorubicin—pancreatic cancer	0.000171	0.000577	CcSEcCtD
Eletriptan—Asthenia—Gemcitabine—pancreatic cancer	0.00017	0.000575	CcSEcCtD
Eletriptan—Confusional state—Docetaxel—pancreatic cancer	0.00017	0.000574	CcSEcCtD
Eletriptan—Oedema—Docetaxel—pancreatic cancer	0.000168	0.000569	CcSEcCtD
Eletriptan—Weight increased—Doxorubicin—pancreatic cancer	0.000168	0.000568	CcSEcCtD
Eletriptan—Epistaxis—Epirubicin—pancreatic cancer	0.000168	0.000568	CcSEcCtD
Eletriptan—Pruritus—Gemcitabine—pancreatic cancer	0.000168	0.000567	CcSEcCtD
Eletriptan—Weight decreased—Doxorubicin—pancreatic cancer	0.000167	0.000565	CcSEcCtD
Eletriptan—Sinusitis—Epirubicin—pancreatic cancer	0.000167	0.000565	CcSEcCtD
Eletriptan—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000167	0.000563	CcSEcCtD
Eletriptan—Diarrhoea—Irinotecan—pancreatic cancer	0.000167	0.000563	CcSEcCtD
Eletriptan—Shock—Docetaxel—pancreatic cancer	0.000166	0.00056	CcSEcCtD
Eletriptan—Nervous system disorder—Docetaxel—pancreatic cancer	0.000165	0.000558	CcSEcCtD
Eletriptan—Pruritus—Fluorouracil—pancreatic cancer	0.000165	0.000558	CcSEcCtD
Eletriptan—Drowsiness—Doxorubicin—pancreatic cancer	0.000165	0.000557	CcSEcCtD
Eletriptan—Tachycardia—Docetaxel—pancreatic cancer	0.000164	0.000555	CcSEcCtD
Eletriptan—Skin disorder—Docetaxel—pancreatic cancer	0.000164	0.000553	CcSEcCtD
Eletriptan—Bradycardia—Epirubicin—pancreatic cancer	0.000163	0.00055	CcSEcCtD
Eletriptan—Diarrhoea—Gemcitabine—pancreatic cancer	0.000162	0.000549	CcSEcCtD
Eletriptan—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000162	0.000546	CcSEcCtD
Eletriptan—Dizziness—Irinotecan—pancreatic cancer	0.000161	0.000544	CcSEcCtD
Eletriptan—Stomatitis—Doxorubicin—pancreatic cancer	0.000161	0.000543	CcSEcCtD
Eletriptan—Anorexia—Docetaxel—pancreatic cancer	0.000161	0.000542	CcSEcCtD
Eletriptan—Rhinitis—Epirubicin—pancreatic cancer	0.00016	0.000542	CcSEcCtD
Eletriptan—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00016	0.000541	CcSEcCtD
Eletriptan—Diarrhoea—Fluorouracil—pancreatic cancer	0.00016	0.000539	CcSEcCtD
Eletriptan—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000159	0.000538	CcSEcCtD
Eletriptan—Pharyngitis—Epirubicin—pancreatic cancer	0.000159	0.000536	CcSEcCtD
Eletriptan—Sweating—Doxorubicin—pancreatic cancer	0.000158	0.000534	CcSEcCtD
Eletriptan—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000158	0.000534	CcSEcCtD
Eletriptan—Oedema peripheral—Epirubicin—pancreatic cancer	0.000158	0.000532	CcSEcCtD
Eletriptan—Hypotension—Docetaxel—pancreatic cancer	0.000157	0.000532	CcSEcCtD
Eletriptan—Urethral disorder—Epirubicin—pancreatic cancer	0.000157	0.00053	CcSEcCtD
Eletriptan—Epistaxis—Doxorubicin—pancreatic cancer	0.000155	0.000525	CcSEcCtD
Eletriptan—Vomiting—Irinotecan—pancreatic cancer	0.000155	0.000523	CcSEcCtD
Eletriptan—Sinusitis—Doxorubicin—pancreatic cancer	0.000155	0.000522	CcSEcCtD
Eletriptan—Dizziness—Fluorouracil—pancreatic cancer	0.000154	0.000521	CcSEcCtD
Eletriptan—Visual impairment—Epirubicin—pancreatic cancer	0.000154	0.000521	CcSEcCtD
Eletriptan—Rash—Irinotecan—pancreatic cancer	0.000154	0.000519	CcSEcCtD
Eletriptan—Dermatitis—Irinotecan—pancreatic cancer	0.000154	0.000519	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000153	0.000518	CcSEcCtD
Eletriptan—Headache—Irinotecan—pancreatic cancer	0.000153	0.000516	CcSEcCtD
Eletriptan—Insomnia—Docetaxel—pancreatic cancer	0.000152	0.000515	CcSEcCtD
Eletriptan—Paraesthesia—Docetaxel—pancreatic cancer	0.000151	0.000511	CcSEcCtD
Eletriptan—Vomiting—Gemcitabine—pancreatic cancer	0.000151	0.00051	CcSEcCtD
Eletriptan—Bradycardia—Doxorubicin—pancreatic cancer	0.000151	0.000509	CcSEcCtD
Eletriptan—Dyspnoea—Docetaxel—pancreatic cancer	0.00015	0.000507	CcSEcCtD
Eletriptan—Somnolence—Docetaxel—pancreatic cancer	0.00015	0.000506	CcSEcCtD
Eletriptan—Rash—Gemcitabine—pancreatic cancer	0.00015	0.000506	CcSEcCtD
Eletriptan—Dermatitis—Gemcitabine—pancreatic cancer	0.00015	0.000505	CcSEcCtD
Eletriptan—Tinnitus—Epirubicin—pancreatic cancer	0.000149	0.000504	CcSEcCtD
Eletriptan—Headache—Gemcitabine—pancreatic cancer	0.000149	0.000502	CcSEcCtD
Eletriptan—Flushing—Epirubicin—pancreatic cancer	0.000148	0.000501	CcSEcCtD
Eletriptan—Vomiting—Fluorouracil—pancreatic cancer	0.000148	0.000501	CcSEcCtD
Eletriptan—Rhinitis—Doxorubicin—pancreatic cancer	0.000148	0.000501	CcSEcCtD
Eletriptan—Dyspepsia—Docetaxel—pancreatic cancer	0.000148	0.000501	CcSEcCtD
Eletriptan—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000147	0.000497	CcSEcCtD
Eletriptan—Rash—Fluorouracil—pancreatic cancer	0.000147	0.000497	CcSEcCtD
Eletriptan—Dermatitis—Fluorouracil—pancreatic cancer	0.000147	0.000497	CcSEcCtD
Eletriptan—Pharyngitis—Doxorubicin—pancreatic cancer	0.000147	0.000496	CcSEcCtD
Eletriptan—Decreased appetite—Docetaxel—pancreatic cancer	0.000146	0.000495	CcSEcCtD
Eletriptan—Headache—Fluorouracil—pancreatic cancer	0.000146	0.000494	CcSEcCtD
Eletriptan—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000146	0.000494	CcSEcCtD
Eletriptan—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000146	0.000492	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000145	0.000491	CcSEcCtD
Eletriptan—Fatigue—Docetaxel—pancreatic cancer	0.000145	0.000491	CcSEcCtD
Eletriptan—Urethral disorder—Doxorubicin—pancreatic cancer	0.000145	0.00049	CcSEcCtD
Eletriptan—Nausea—Irinotecan—pancreatic cancer	0.000145	0.000489	CcSEcCtD
Eletriptan—Immune system disorder—Epirubicin—pancreatic cancer	0.000144	0.000488	CcSEcCtD
Eletriptan—Constipation—Docetaxel—pancreatic cancer	0.000144	0.000487	CcSEcCtD
Eletriptan—Pain—Docetaxel—pancreatic cancer	0.000144	0.000487	CcSEcCtD
Eletriptan—Chills—Epirubicin—pancreatic cancer	0.000144	0.000485	CcSEcCtD
Eletriptan—Arrhythmia—Epirubicin—pancreatic cancer	0.000143	0.000483	CcSEcCtD
Eletriptan—Visual impairment—Doxorubicin—pancreatic cancer	0.000143	0.000482	CcSEcCtD
Eletriptan—Alopecia—Epirubicin—pancreatic cancer	0.000141	0.000477	CcSEcCtD
Eletriptan—Nausea—Gemcitabine—pancreatic cancer	0.000141	0.000476	CcSEcCtD
Eletriptan—Feeling abnormal—Docetaxel—pancreatic cancer	0.000139	0.000469	CcSEcCtD
Eletriptan—Nausea—Fluorouracil—pancreatic cancer	0.000139	0.000468	CcSEcCtD
Eletriptan—Tinnitus—Doxorubicin—pancreatic cancer	0.000138	0.000466	CcSEcCtD
Eletriptan—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000138	0.000465	CcSEcCtD
Eletriptan—Flushing—Doxorubicin—pancreatic cancer	0.000137	0.000464	CcSEcCtD
Eletriptan—Flatulence—Epirubicin—pancreatic cancer	0.000137	0.000463	CcSEcCtD
Eletriptan—Tension—Epirubicin—pancreatic cancer	0.000137	0.000461	CcSEcCtD
Eletriptan—Dysgeusia—Epirubicin—pancreatic cancer	0.000136	0.000461	CcSEcCtD
Eletriptan—Nervousness—Epirubicin—pancreatic cancer	0.000135	0.000457	CcSEcCtD
Eletriptan—Back pain—Epirubicin—pancreatic cancer	0.000135	0.000455	CcSEcCtD
Eletriptan—Muscle spasms—Epirubicin—pancreatic cancer	0.000134	0.000452	CcSEcCtD
Eletriptan—Immune system disorder—Doxorubicin—pancreatic cancer	0.000134	0.000451	CcSEcCtD
Eletriptan—Body temperature increased—Docetaxel—pancreatic cancer	0.000133	0.00045	CcSEcCtD
Eletriptan—Abdominal pain—Docetaxel—pancreatic cancer	0.000133	0.00045	CcSEcCtD
Eletriptan—Chills—Doxorubicin—pancreatic cancer	0.000133	0.000449	CcSEcCtD
Eletriptan—Arrhythmia—Doxorubicin—pancreatic cancer	0.000132	0.000447	CcSEcCtD
Eletriptan—Alopecia—Doxorubicin—pancreatic cancer	0.000131	0.000442	CcSEcCtD
Eletriptan—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000129	0.000436	CcSEcCtD
Eletriptan—Anaemia—Epirubicin—pancreatic cancer	0.000129	0.000435	CcSEcCtD
Eletriptan—Agitation—Epirubicin—pancreatic cancer	0.000128	0.000432	CcSEcCtD
Eletriptan—Flatulence—Doxorubicin—pancreatic cancer	0.000127	0.000429	CcSEcCtD
Eletriptan—Tension—Doxorubicin—pancreatic cancer	0.000126	0.000427	CcSEcCtD
Eletriptan—Dysgeusia—Doxorubicin—pancreatic cancer	0.000126	0.000426	CcSEcCtD
Eletriptan—Malaise—Epirubicin—pancreatic cancer	0.000126	0.000424	CcSEcCtD
Eletriptan—Nervousness—Doxorubicin—pancreatic cancer	0.000125	0.000423	CcSEcCtD
Eletriptan—Vertigo—Epirubicin—pancreatic cancer	0.000125	0.000423	CcSEcCtD
Eletriptan—Syncope—Epirubicin—pancreatic cancer	0.000125	0.000422	CcSEcCtD
Eletriptan—Leukopenia—Epirubicin—pancreatic cancer	0.000125	0.000421	CcSEcCtD
Eletriptan—Back pain—Doxorubicin—pancreatic cancer	0.000125	0.000421	CcSEcCtD
Eletriptan—Hypersensitivity—Docetaxel—pancreatic cancer	0.000124	0.000419	CcSEcCtD
Eletriptan—Muscle spasms—Doxorubicin—pancreatic cancer	0.000124	0.000418	CcSEcCtD
Eletriptan—Palpitations—Epirubicin—pancreatic cancer	0.000123	0.000416	CcSEcCtD
Eletriptan—Loss of consciousness—Epirubicin—pancreatic cancer	0.000122	0.000413	CcSEcCtD
Eletriptan—Cough—Epirubicin—pancreatic cancer	0.000121	0.00041	CcSEcCtD
Eletriptan—Asthenia—Docetaxel—pancreatic cancer	0.000121	0.000408	CcSEcCtD
Eletriptan—Convulsion—Epirubicin—pancreatic cancer	0.000121	0.000407	CcSEcCtD
Eletriptan—Hypertension—Epirubicin—pancreatic cancer	0.00012	0.000406	CcSEcCtD
Eletriptan—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.00012	0.000404	CcSEcCtD
Eletriptan—Pruritus—Docetaxel—pancreatic cancer	0.000119	0.000403	CcSEcCtD
Eletriptan—Anaemia—Doxorubicin—pancreatic cancer	0.000119	0.000402	CcSEcCtD
Eletriptan—Arthralgia—Epirubicin—pancreatic cancer	0.000119	0.0004	CcSEcCtD
Eletriptan—Myalgia—Epirubicin—pancreatic cancer	0.000119	0.0004	CcSEcCtD
Eletriptan—Agitation—Doxorubicin—pancreatic cancer	0.000118	0.0004	CcSEcCtD
Eletriptan—Anxiety—Epirubicin—pancreatic cancer	0.000118	0.000399	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000118	0.000398	CcSEcCtD
Eletriptan—Discomfort—Epirubicin—pancreatic cancer	0.000117	0.000396	CcSEcCtD
Eletriptan—Malaise—Doxorubicin—pancreatic cancer	0.000116	0.000392	CcSEcCtD
Eletriptan—Dry mouth—Epirubicin—pancreatic cancer	0.000116	0.000392	CcSEcCtD
Eletriptan—Vertigo—Doxorubicin—pancreatic cancer	0.000116	0.000391	CcSEcCtD
Eletriptan—Syncope—Doxorubicin—pancreatic cancer	0.000116	0.00039	CcSEcCtD
Eletriptan—Leukopenia—Doxorubicin—pancreatic cancer	0.000115	0.000389	CcSEcCtD
Eletriptan—Diarrhoea—Docetaxel—pancreatic cancer	0.000115	0.000389	CcSEcCtD
Eletriptan—Confusional state—Epirubicin—pancreatic cancer	0.000115	0.000387	CcSEcCtD
Eletriptan—Palpitations—Doxorubicin—pancreatic cancer	0.000114	0.000385	CcSEcCtD
Eletriptan—Oedema—Epirubicin—pancreatic cancer	0.000114	0.000384	CcSEcCtD
Eletriptan—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000113	0.000382	CcSEcCtD
Eletriptan—Cough—Doxorubicin—pancreatic cancer	0.000112	0.00038	CcSEcCtD
Eletriptan—Shock—Epirubicin—pancreatic cancer	0.000112	0.000378	CcSEcCtD
Eletriptan—Convulsion—Doxorubicin—pancreatic cancer	0.000112	0.000377	CcSEcCtD
Eletriptan—Nervous system disorder—Epirubicin—pancreatic cancer	0.000111	0.000376	CcSEcCtD
Eletriptan—Dizziness—Docetaxel—pancreatic cancer	0.000111	0.000376	CcSEcCtD
Eletriptan—Hypertension—Doxorubicin—pancreatic cancer	0.000111	0.000376	CcSEcCtD
Eletriptan—Tachycardia—Epirubicin—pancreatic cancer	0.000111	0.000375	CcSEcCtD
Eletriptan—Skin disorder—Epirubicin—pancreatic cancer	0.00011	0.000373	CcSEcCtD
Eletriptan—Hyperhidrosis—Epirubicin—pancreatic cancer	0.00011	0.000371	CcSEcCtD
Eletriptan—Arthralgia—Doxorubicin—pancreatic cancer	0.00011	0.00037	CcSEcCtD
Eletriptan—Myalgia—Doxorubicin—pancreatic cancer	0.00011	0.00037	CcSEcCtD
Eletriptan—Anxiety—Doxorubicin—pancreatic cancer	0.000109	0.000369	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000109	0.000368	CcSEcCtD
Eletriptan—Discomfort—Doxorubicin—pancreatic cancer	0.000108	0.000366	CcSEcCtD
Eletriptan—Anorexia—Epirubicin—pancreatic cancer	0.000108	0.000366	CcSEcCtD
Eletriptan—Dry mouth—Doxorubicin—pancreatic cancer	0.000107	0.000362	CcSEcCtD
Eletriptan—Vomiting—Docetaxel—pancreatic cancer	0.000107	0.000362	CcSEcCtD
Eletriptan—Rash—Docetaxel—pancreatic cancer	0.000106	0.000359	CcSEcCtD
Eletriptan—Hypotension—Epirubicin—pancreatic cancer	0.000106	0.000359	CcSEcCtD
Eletriptan—Dermatitis—Docetaxel—pancreatic cancer	0.000106	0.000358	CcSEcCtD
Eletriptan—Confusional state—Doxorubicin—pancreatic cancer	0.000106	0.000358	CcSEcCtD
Eletriptan—Headache—Docetaxel—pancreatic cancer	0.000106	0.000356	CcSEcCtD
Eletriptan—Oedema—Doxorubicin—pancreatic cancer	0.000105	0.000355	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000104	0.00035	CcSEcCtD
Eletriptan—Shock—Doxorubicin—pancreatic cancer	0.000103	0.000349	CcSEcCtD
Eletriptan—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000103	0.000348	CcSEcCtD
Eletriptan—Insomnia—Epirubicin—pancreatic cancer	0.000103	0.000347	CcSEcCtD
Eletriptan—Tachycardia—Doxorubicin—pancreatic cancer	0.000103	0.000347	CcSEcCtD
Eletriptan—Skin disorder—Doxorubicin—pancreatic cancer	0.000102	0.000345	CcSEcCtD
Eletriptan—Paraesthesia—Epirubicin—pancreatic cancer	0.000102	0.000345	CcSEcCtD
Eletriptan—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000102	0.000343	CcSEcCtD
Eletriptan—Dyspnoea—Epirubicin—pancreatic cancer	0.000101	0.000342	CcSEcCtD
Eletriptan—Somnolence—Epirubicin—pancreatic cancer	0.000101	0.000341	CcSEcCtD
Eletriptan—Anorexia—Doxorubicin—pancreatic cancer	0.0001	0.000339	CcSEcCtD
Eletriptan—Nausea—Docetaxel—pancreatic cancer	0.0001	0.000338	CcSEcCtD
Eletriptan—Dyspepsia—Epirubicin—pancreatic cancer	0.0001	0.000338	CcSEcCtD
Eletriptan—Decreased appetite—Epirubicin—pancreatic cancer	9.88e-05	0.000334	CcSEcCtD
Eletriptan—Hypotension—Doxorubicin—pancreatic cancer	9.82e-05	0.000332	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.81e-05	0.000331	CcSEcCtD
Eletriptan—Fatigue—Epirubicin—pancreatic cancer	9.8e-05	0.000331	CcSEcCtD
Eletriptan—Constipation—Epirubicin—pancreatic cancer	9.72e-05	0.000328	CcSEcCtD
Eletriptan—Pain—Epirubicin—pancreatic cancer	9.72e-05	0.000328	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	9.58e-05	0.000324	CcSEcCtD
Eletriptan—Insomnia—Doxorubicin—pancreatic cancer	9.51e-05	0.000321	CcSEcCtD
Eletriptan—Paraesthesia—Doxorubicin—pancreatic cancer	9.44e-05	0.000319	CcSEcCtD
Eletriptan—Dyspnoea—Doxorubicin—pancreatic cancer	9.37e-05	0.000317	CcSEcCtD
Eletriptan—Feeling abnormal—Epirubicin—pancreatic cancer	9.36e-05	0.000316	CcSEcCtD
Eletriptan—Somnolence—Doxorubicin—pancreatic cancer	9.35e-05	0.000316	CcSEcCtD
Eletriptan—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.29e-05	0.000314	CcSEcCtD
Eletriptan—Dyspepsia—Doxorubicin—pancreatic cancer	9.25e-05	0.000313	CcSEcCtD
Eletriptan—Decreased appetite—Doxorubicin—pancreatic cancer	9.14e-05	0.000309	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	9.08e-05	0.000307	CcSEcCtD
Eletriptan—Fatigue—Doxorubicin—pancreatic cancer	9.06e-05	0.000306	CcSEcCtD
Eletriptan—Urticaria—Epirubicin—pancreatic cancer	9.03e-05	0.000305	CcSEcCtD
Eletriptan—Pain—Doxorubicin—pancreatic cancer	8.99e-05	0.000304	CcSEcCtD
Eletriptan—Constipation—Doxorubicin—pancreatic cancer	8.99e-05	0.000304	CcSEcCtD
Eletriptan—Abdominal pain—Epirubicin—pancreatic cancer	8.98e-05	0.000303	CcSEcCtD
Eletriptan—Body temperature increased—Epirubicin—pancreatic cancer	8.98e-05	0.000303	CcSEcCtD
Eletriptan—Feeling abnormal—Doxorubicin—pancreatic cancer	8.66e-05	0.000293	CcSEcCtD
Eletriptan—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.6e-05	0.00029	CcSEcCtD
Eletriptan—Hypersensitivity—Epirubicin—pancreatic cancer	8.37e-05	0.000283	CcSEcCtD
Eletriptan—Urticaria—Doxorubicin—pancreatic cancer	8.35e-05	0.000282	CcSEcCtD
Eletriptan—Body temperature increased—Doxorubicin—pancreatic cancer	8.31e-05	0.000281	CcSEcCtD
Eletriptan—Abdominal pain—Doxorubicin—pancreatic cancer	8.31e-05	0.000281	CcSEcCtD
Eletriptan—Asthenia—Epirubicin—pancreatic cancer	8.15e-05	0.000275	CcSEcCtD
Eletriptan—Pruritus—Epirubicin—pancreatic cancer	8.04e-05	0.000272	CcSEcCtD
Eletriptan—Diarrhoea—Epirubicin—pancreatic cancer	7.77e-05	0.000263	CcSEcCtD
Eletriptan—Hypersensitivity—Doxorubicin—pancreatic cancer	7.75e-05	0.000262	CcSEcCtD
Eletriptan—Asthenia—Doxorubicin—pancreatic cancer	7.54e-05	0.000255	CcSEcCtD
Eletriptan—Dizziness—Epirubicin—pancreatic cancer	7.51e-05	0.000254	CcSEcCtD
Eletriptan—Pruritus—Doxorubicin—pancreatic cancer	7.44e-05	0.000251	CcSEcCtD
Eletriptan—Vomiting—Epirubicin—pancreatic cancer	7.22e-05	0.000244	CcSEcCtD
Eletriptan—Diarrhoea—Doxorubicin—pancreatic cancer	7.19e-05	0.000243	CcSEcCtD
Eletriptan—Rash—Epirubicin—pancreatic cancer	7.16e-05	0.000242	CcSEcCtD
Eletriptan—Dermatitis—Epirubicin—pancreatic cancer	7.16e-05	0.000242	CcSEcCtD
Eletriptan—Headache—Epirubicin—pancreatic cancer	7.12e-05	0.00024	CcSEcCtD
Eletriptan—Dizziness—Doxorubicin—pancreatic cancer	6.95e-05	0.000235	CcSEcCtD
Eletriptan—Nausea—Epirubicin—pancreatic cancer	6.75e-05	0.000228	CcSEcCtD
Eletriptan—Vomiting—Doxorubicin—pancreatic cancer	6.68e-05	0.000226	CcSEcCtD
Eletriptan—Rash—Doxorubicin—pancreatic cancer	6.63e-05	0.000224	CcSEcCtD
Eletriptan—Dermatitis—Doxorubicin—pancreatic cancer	6.62e-05	0.000224	CcSEcCtD
Eletriptan—Headache—Doxorubicin—pancreatic cancer	6.59e-05	0.000222	CcSEcCtD
Eletriptan—Nausea—Doxorubicin—pancreatic cancer	6.24e-05	0.000211	CcSEcCtD
Eletriptan—HTR1D—Signaling Pathways—PIK3CD—pancreatic cancer	1.46e-05	0.000106	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.46e-05	0.000106	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—STAT3—pancreatic cancer	1.45e-05	0.000105	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CD44—pancreatic cancer	1.45e-05	0.000105	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—NRAS—pancreatic cancer	1.45e-05	0.000105	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.45e-05	0.000105	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—KRAS—pancreatic cancer	1.44e-05	0.000104	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CG—pancreatic cancer	1.43e-05	0.000104	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CD—pancreatic cancer	1.43e-05	0.000104	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—KRAS—pancreatic cancer	1.43e-05	0.000104	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—MYC—pancreatic cancer	1.43e-05	0.000104	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TGFB1—pancreatic cancer	1.43e-05	0.000103	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.42e-05	0.000103	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.42e-05	0.000103	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CD44—pancreatic cancer	1.42e-05	0.000103	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.41e-05	0.000102	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HIF1A—pancreatic cancer	1.41e-05	0.000102	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TSC2—pancreatic cancer	1.41e-05	0.000102	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—KRAS—pancreatic cancer	1.4e-05	0.000102	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—EGFR—pancreatic cancer	1.4e-05	0.000101	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—EGFR—pancreatic cancer	1.4e-05	0.000101	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GCG—pancreatic cancer	1.39e-05	0.000101	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PPARG—pancreatic cancer	1.38e-05	0.0001	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—APOE—pancreatic cancer	1.38e-05	9.96e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GCG—pancreatic cancer	1.36e-05	9.84e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CG—pancreatic cancer	1.36e-05	9.81e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—MYC—pancreatic cancer	1.35e-05	9.78e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TGFB1—pancreatic cancer	1.35e-05	9.75e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KDR—pancreatic cancer	1.35e-05	9.75e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CD—pancreatic cancer	1.35e-05	9.74e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CD44—pancreatic cancer	1.34e-05	9.67e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.33e-05	9.65e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—PIK3CA—pancreatic cancer	1.33e-05	9.59e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CD44—pancreatic cancer	1.33e-05	9.59e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—KRAS—pancreatic cancer	1.32e-05	9.58e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—EGFR—pancreatic cancer	1.32e-05	9.56e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—KRAS—pancreatic cancer	1.32e-05	9.54e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—PIK3CA—pancreatic cancer	1.32e-05	9.52e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—STK11—pancreatic cancer	1.31e-05	9.48e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PPARG—pancreatic cancer	1.31e-05	9.47e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.3e-05	9.39e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—PIK3CA—pancreatic cancer	1.29e-05	9.33e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.29e-05	9.3e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CB—pancreatic cancer	1.28e-05	9.29e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NFKBIA—pancreatic cancer	1.28e-05	9.28e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GCG—pancreatic cancer	1.28e-05	9.27e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—STK11—pancreatic cancer	1.28e-05	9.25e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CB—pancreatic cancer	1.28e-05	9.23e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GCG—pancreatic cancer	1.27e-05	9.19e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NOTCH1—pancreatic cancer	1.27e-05	9.19e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CD—pancreatic cancer	1.26e-05	9.12e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CB—pancreatic cancer	1.25e-05	9.04e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—KRAS—pancreatic cancer	1.25e-05	9.03e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CG—pancreatic cancer	1.24e-05	8.98e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—NRAS—pancreatic cancer	1.24e-05	8.98e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCL8—pancreatic cancer	1.23e-05	8.93e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.23e-05	8.9e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGF—pancreatic cancer	1.23e-05	8.88e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—HRAS—pancreatic cancer	1.23e-05	8.87e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCL8—pancreatic cancer	1.23e-05	8.87e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—HRAS—pancreatic cancer	1.22e-05	8.81e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—PIK3CA—pancreatic cancer	1.22e-05	8.8e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—PIK3CA—pancreatic cancer	1.21e-05	8.76e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.21e-05	8.74e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—STK11—pancreatic cancer	1.2e-05	8.72e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCL8—pancreatic cancer	1.2e-05	8.68e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—STK11—pancreatic cancer	1.19e-05	8.64e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—HRAS—pancreatic cancer	1.19e-05	8.63e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CD—pancreatic cancer	1.19e-05	8.63e-05	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—AKT1—pancreatic cancer	1.19e-05	8.62e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.19e-05	8.6e-05	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—AKT1—pancreatic cancer	1.18e-05	8.57e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CASP3—pancreatic cancer	1.18e-05	8.54e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TP53—pancreatic cancer	1.18e-05	8.51e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CB—pancreatic cancer	1.17e-05	8.49e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CASP3—pancreatic cancer	1.17e-05	8.49e-05	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—AKT1—pancreatic cancer	1.16e-05	8.39e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCND1—pancreatic cancer	1.15e-05	8.32e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CASP3—pancreatic cancer	1.15e-05	8.31e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—PIK3CA—pancreatic cancer	1.15e-05	8.3e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCND1—pancreatic cancer	1.14e-05	8.26e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CTNNB1—pancreatic cancer	1.14e-05	8.24e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	1.13e-05	8.19e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CTNNB1—pancreatic cancer	1.13e-05	8.18e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.13e-05	8.16e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL8—pancreatic cancer	1.13e-05	8.16e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—TYMS—pancreatic cancer	1.13e-05	8.15e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—HRAS—pancreatic cancer	1.13e-05	8.14e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.12e-05	8.11e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—HRAS—pancreatic cancer	1.12e-05	8.11e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—pancreatic cancer	1.12e-05	8.09e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MMP9—pancreatic cancer	1.12e-05	8.07e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—pancreatic cancer	1.11e-05	8.03e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PTEN—pancreatic cancer	1.11e-05	8.03e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MMP9—pancreatic cancer	1.11e-05	8.02e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CTNNB1—pancreatic cancer	1.11e-05	8.01e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PTEN—pancreatic cancer	1.1e-05	7.98e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—TYMS—pancreatic cancer	1.1e-05	7.96e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CB—pancreatic cancer	1.1e-05	7.95e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	1.09e-05	7.9e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	1.09e-05	7.88e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTGS2—pancreatic cancer	1.09e-05	7.88e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MMP9—pancreatic cancer	1.09e-05	7.86e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—AKT1—pancreatic cancer	1.08e-05	7.83e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.08e-05	7.82e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PTEN—pancreatic cancer	1.08e-05	7.81e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	1.08e-05	7.81e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—AKT1—pancreatic cancer	1.08e-05	7.78e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	1.07e-05	7.73e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—HRAS—pancreatic cancer	1.06e-05	7.68e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—AKT1—pancreatic cancer	1.05e-05	7.62e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	1.05e-05	7.6e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	1.04e-05	7.53e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CB—pancreatic cancer	1.04e-05	7.52e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.04e-05	7.5e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTGS2—pancreatic cancer	1.03e-05	7.45e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—SRC—pancreatic cancer	1.03e-05	7.44e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—TYMS—pancreatic cancer	1.03e-05	7.43e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—SRC—pancreatic cancer	1.02e-05	7.4e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	1.02e-05	7.38e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	1.01e-05	7.34e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—pancreatic cancer	1e-05	7.25e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—SRC—pancreatic cancer	1e-05	7.24e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—pancreatic cancer	9.96e-06	7.2e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—AKT1—pancreatic cancer	9.94e-06	7.19e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—pancreatic cancer	9.92e-06	7.18e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NRAS—pancreatic cancer	9.9e-06	7.16e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	9.89e-06	7.16e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—pancreatic cancer	9.86e-06	7.13e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NRAS—pancreatic cancer	9.84e-06	7.12e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	9.82e-06	7.1e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—pancreatic cancer	9.75e-06	7.05e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—pancreatic cancer	9.65e-06	6.98e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NRAS—pancreatic cancer	9.63e-06	6.97e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	9.52e-06	6.88e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTEN—pancreatic cancer	9.5e-06	6.87e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SRC—pancreatic cancer	9.4e-06	6.8e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—AKT1—pancreatic cancer	9.37e-06	6.78e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—pancreatic cancer	9.22e-06	6.67e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TGFB1—pancreatic cancer	9.2e-06	6.66e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—APOE—pancreatic cancer	9.16e-06	6.63e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—pancreatic cancer	9.16e-06	6.63e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	9.16e-06	6.63e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	9.15e-06	6.62e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TGFB1—pancreatic cancer	9.14e-06	6.61e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	9.09e-06	6.57e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	9.07e-06	6.56e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	9.05e-06	6.54e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EGFR—pancreatic cancer	9.02e-06	6.53e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTEN—pancreatic cancer	8.98e-06	6.5e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—pancreatic cancer	8.97e-06	6.49e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EGFR—pancreatic cancer	8.96e-06	6.48e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	8.95e-06	6.47e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—APOE—pancreatic cancer	8.94e-06	6.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	8.83e-06	6.39e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	8.77e-06	6.35e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	8.75e-06	6.33e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CD44—pancreatic cancer	8.74e-06	6.32e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.67e-06	6.28e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KRAS—pancreatic cancer	8.52e-06	6.16e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	8.52e-06	6.16e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	8.47e-06	6.12e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	8.44e-06	6.1e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—APOE—pancreatic cancer	8.43e-06	6.1e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—pancreatic cancer	8.43e-06	6.1e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	8.41e-06	6.08e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GCG—pancreatic cancer	8.38e-06	6.06e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—APOE—pancreatic cancer	8.36e-06	6.04e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	8.29e-06	6e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	8.27e-06	5.98e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	8.27e-06	5.98e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	8.24e-06	5.96e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	8.22e-06	5.95e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CG—pancreatic cancer	8.07e-06	5.84e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	8.02e-06	5.8e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPARG—pancreatic cancer	7.98e-06	5.77e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.91e-06	5.72e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—STK11—pancreatic cancer	7.88e-06	5.7e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	7.83e-06	5.66e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPARG—pancreatic cancer	7.79e-06	5.64e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	7.79e-06	5.63e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	7.78e-06	5.63e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SRC—pancreatic cancer	7.63e-06	5.52e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	7.62e-06	5.51e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	7.61e-06	5.5e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—pancreatic cancer	7.57e-06	5.48e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	7.54e-06	5.46e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—pancreatic cancer	7.52e-06	5.44e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	7.43e-06	5.37e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—pancreatic cancer	7.37e-06	5.33e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	7.35e-06	5.32e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPARG—pancreatic cancer	7.34e-06	5.31e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	7.34e-06	5.31e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPARG—pancreatic cancer	7.28e-06	5.27e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	7.27e-06	5.26e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—HRAS—pancreatic cancer	7.24e-06	5.24e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	7.2e-06	5.21e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	7.15e-06	5.18e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CD—pancreatic cancer	7.1e-06	5.13e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	7.05e-06	5.1e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—pancreatic cancer	6.92e-06	5.01e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—pancreatic cancer	6.83e-06	4.94e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	6.82e-06	4.93e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TYMS—pancreatic cancer	6.78e-06	4.9e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CA—pancreatic cancer	6.7e-06	4.85e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	6.69e-06	4.84e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	6.68e-06	4.84e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	6.63e-06	4.8e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	6.62e-06	4.79e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—AKT1—pancreatic cancer	6.4e-06	4.63e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	6.35e-06	4.6e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	6.34e-06	4.58e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CA—pancreatic cancer	6.34e-06	4.58e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	6.31e-06	4.57e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS2—pancreatic cancer	6.28e-06	4.54e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	6.22e-06	4.5e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CB—pancreatic cancer	6.19e-06	4.47e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS2—pancreatic cancer	6.13e-06	4.43e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	5.84e-06	4.23e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	5.83e-06	4.22e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	5.8e-06	4.2e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	5.78e-06	4.18e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS2—pancreatic cancer	5.78e-06	4.18e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS2—pancreatic cancer	5.73e-06	4.14e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—pancreatic cancer	5.61e-06	4.06e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOE—pancreatic cancer	5.51e-06	3.99e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTEN—pancreatic cancer	5.48e-06	3.96e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AKT1—pancreatic cancer	5.47e-06	3.96e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	5.37e-06	3.88e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTEN—pancreatic cancer	5.34e-06	3.87e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AKT1—pancreatic cancer	5.18e-06	3.74e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTEN—pancreatic cancer	5.04e-06	3.64e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTEN—pancreatic cancer	4.99e-06	3.61e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	4.97e-06	3.6e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPARG—pancreatic cancer	4.8e-06	3.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	4.74e-06	3.43e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	4.37e-06	3.16e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	3.86e-06	2.79e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	3.81e-06	2.76e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS2—pancreatic cancer	3.78e-06	2.73e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CA—pancreatic cancer	3.77e-06	2.73e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3.55e-06	2.57e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	3.52e-06	2.55e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTEN—pancreatic cancer	3.29e-06	2.38e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AKT1—pancreatic cancer	3.16e-06	2.28e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AKT1—pancreatic cancer	3.08e-06	2.23e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.9e-06	2.1e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.88e-06	2.08e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	2.32e-06	1.68e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.9e-06	1.37e-05	CbGpPWpGaD
